SG Americas Securities LLC Sells 15,666 Shares of FibroGen, Inc. (NASDAQ:FGEN)

SG Americas Securities LLC reduced its position in shares of FibroGen, Inc. (NASDAQ:FGENGet Rating) by 26.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 42,545 shares of the biopharmaceutical company’s stock after selling 15,666 shares during the quarter. SG Americas Securities LLC’s holdings in FibroGen were worth $554,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its position in FibroGen by 67.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 8,841 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 3,551 shares in the last quarter. Institute for Wealth Management LLC. raised its position in FibroGen by 2.5% during the third quarter. Institute for Wealth Management LLC. now owns 27,361 shares of the biopharmaceutical company’s stock worth $356,000 after acquiring an additional 669 shares in the last quarter. Newbridge Financial Services Group Inc. raised its position in FibroGen by 9.4% during the third quarter. Newbridge Financial Services Group Inc. now owns 20,285 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 1,750 shares in the last quarter. Mackenzie Financial Corp bought a new stake in FibroGen during the third quarter worth $517,000. Finally, Walleye Capital LLC raised its position in FibroGen by 16.6% during the second quarter. Walleye Capital LLC now owns 184,406 shares of the biopharmaceutical company’s stock worth $1,947,000 after acquiring an additional 26,315 shares in the last quarter. 76.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on FGEN shares. StockNews.com started coverage on shares of FibroGen in a research report on Wednesday, October 12th. They issued a “hold” rating on the stock. Bank of America raised shares of FibroGen from a “neutral” rating to a “buy” rating and increased their price objective for the company from $18.00 to $27.00 in a research report on Thursday, January 5th.

FibroGen Price Performance

Shares of FGEN opened at $20.02 on Tuesday. The firm has a market capitalization of $1.88 billion, a PE ratio of -5.15 and a beta of 0.77. The company’s 50-day moving average is $16.27 and its 200-day moving average is $14.71. FibroGen, Inc. has a fifty-two week low of $7.81 and a fifty-two week high of $21.30.

FibroGen (NASDAQ:FGENGet Rating) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.15). FibroGen had a negative net margin of 294.16% and a negative return on equity of 250.58%. The company had revenue of $15.74 million during the quarter, compared to the consensus estimate of $34.02 million. Analysts predict that FibroGen, Inc. will post -3.37 earnings per share for the current fiscal year.

Insider Activity at FibroGen

In related news, CEO Enrique A. Conterno sold 1,538 shares of the company’s stock in a transaction dated Friday, January 6th. The shares were sold at an average price of $19.95, for a total value of $30,683.10. Following the transaction, the chief executive officer now directly owns 295,483 shares in the company, valued at $5,894,885.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Enrique A. Conterno sold 1,538 shares of the company’s stock in a transaction dated Friday, January 6th. The shares were sold at an average price of $19.95, for a total value of $30,683.10. Following the transaction, the chief executive officer now directly owns 295,483 shares in the company, valued at $5,894,885.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Enrique A. Conterno sold 2,543 shares of the company’s stock in a transaction dated Thursday, December 8th. The shares were sold at an average price of $15.79, for a total transaction of $40,153.97. Following the completion of the transaction, the chief executive officer now owns 297,020 shares in the company, valued at $4,689,945.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,481 shares of company stock worth $137,810. Corporate insiders own 2.82% of the company’s stock.

About FibroGen

(Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

See Also

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc. (NASDAQ:FGENGet Rating).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.